Insights provides context and perspective about key pharmacy trends and issues

Identifying Gaps in Care for Rheumatoid Arthritis
Cost Management
CVS Health research highlights gaps in diagnosis and treatment of rheumatoid arthritis to help address cost, care, and patient outcomes. More
Briefing
Cost Management
Changes to CVS Caremark template formularies effective January 1, 2021 continue our legacy of innovation as well as delivering value and quality care — helping clients save money while... More
Briefing
Cost Management
As part of the CVS Health hyperinflation strategy, our Outlier Pharmacy Program proactively monitors and identifies pharmacies with increased volume in claims submissions of certain drugs. More
Briefing
Cost Management
Our enhanced SGM criteria generates greater efficiencies for better cost management, while improving clinically appropriate interventions. More
Briefing
Cost Management
Purpose-built formulary management and network management strategies from CVS Health are designed to help lower plan costs with minimal member disruption. More
Briefing
Cost Management
CVS Health offers payors a new stop-loss program and installment payment plan to help mitigate the large one-time impact of costly gene therapies. These approaches are part of four... More
Briefing
A couple stroll together on the beach
Cost Management
In 2019, drug trend for CVS Caremark pharmacy benefit clients was a historically low, industry-leading 1.4 percent, with 41% of clients seeing negative trend. Specialty trend was in the... More
Feature
Cost Management
Our new RxZERO plan design fordiabetes eliminates member out-of-pocket costs, and enables clients to help membersimprove health outcomes without raising premiums or deductibles More
White Paper
Cost Management
Gene therapies have the potential to relieve tremendous suffering for patients with genetic disorders and together we can find ways to ensure these treatments are accessible for all those... More
White Paper
Cost Management
Payors are projected to save on per-member-per-month costs from strategic formulary removals designed to help mitigate the effect of high-cost and hyperinflationary drugs More
Briefing